Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$2.41 - $7.11 $73,815 - $217,772
-30,629 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$9.37 - $12.06 $13,914 - $17,909
-1,485 Reduced 4.62%
30,629 $332,000
Q2 2020

Aug 14, 2020

BUY
$8.29 - $11.47 $266,225 - $368,347
32,114 New
32,114 $346,000

About AVENUE THERAPEUTICS, INC.


  • Ticker ATXI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,127,720
  • Market Cap $13.8M
  • Description
  • Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...
More about ATXI
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.